Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
administered, analyze, awaiting, Barovic, bound, breach, carefully, carryforward, cisplatin, clarification, Code, commence, commenced, complaint, Corrupt, County, damage, deferred, depreciation, desire, disallowance, disinterested, duty, enrichment, equipment, equitable, erosion, established, expenditure, FCPA, fewer, fiduciary, framework, gemcitabine, hold, Ind, influence, interim, issuance, IV, Kim, low, magnitude, Marion, matter, narrowed, nominal, nonclinical, notional, oversight, paclitaxel, peglispro, permitted, Pfizer, Pharma, Priority, proceeding, proper, property, prospective, purportedly, RAINBOW, receipt, recurrent, refinancing, relief, retail, ROSE, speed, SQUIRE, stayed, Sun, tanezumab, thereof, unchanged, unjust, unspecified, upcoming, waste
Removed:
affirmed, begin, case, developed, medicine, promoted, scheduled, Supreme, utero, validity
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 11 Computation of Earnings Per Share
- 12 Computation of Ratio of Earnings (Loss) to Fixed Charges
- 31.1 Rule 13A-14(A) Certification of John C. Lechleiter, Chairman, President, and Chi
- 31.2 Rule 13A-14(A) Certification of Derica W. Rice, Executive Vice President, Global
- 32 Section 1350 Certification
- Download Excel data file
- View Excel data file
Related press release
LLY similar filings
Filing view
External links
EXHIBIT 11. Statement Re: Computation of Earnings Per Share
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||
(Dollars and shares in millions, except per-share data) | ||||||||||||||||
BASIC | ||||||||||||||||
Net income | $ | 1,203.1 | $ | 1,326.6 | $ | 3,957.3 | $ | 3,261.3 | ||||||||
Average number of common shares outstanding | 1,076.6 | 1,110.4 | 1,079.1 | 1,110.3 | ||||||||||||
Contingently issuable shares | 3.6 | 9.2 | 3.7 | 8.1 | ||||||||||||
Adjusted average shares | 1,080.2 | 1,119.6 | 1,082.8 | 1,118.4 | ||||||||||||
Basic earnings per share | $ | 1.11 | $ | 1.18 | $ | 3.65 | $ | 2.92 | ||||||||
DILUTED | ||||||||||||||||
Net income | $ | 1,203.1 | $ | 1,326.6 | $ | 3,957.3 | $ | 3,261.3 | ||||||||
Average number of common shares outstanding | 1,076.6 | 1,110.4 | 1,079.1 | 1,110.3 | ||||||||||||
Incremental shares – stock options and contingently issuable shares | 7.6 | 9.2 | 7.6 | 8.1 | ||||||||||||
Adjusted average shares | 1,084.2 | 1,119.6 | 1,086.7 | 1,118.4 | ||||||||||||
Diluted earnings per share | $ | 1.11 | $ | 1.18 | $ | 3.64 | $ | 2.92 |